請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56502
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張睿詒 | |
dc.contributor.author | Yi-Chen Chang | en |
dc.contributor.author | 張益誠 | zh_TW |
dc.date.accessioned | 2021-06-16T05:31:47Z | - |
dc.date.available | 2014-10-20 | |
dc.date.copyright | 2014-10-20 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-13 | |
dc.identifier.citation | 1. 中華民國98 年癌症登記報告。行政院衛生署國民健康局編印
2. Dedhia RC, Smith KJ, Johnson JT, Roberts M. The cost-effectiveness of community-based screening for oral cancer in high-risk males in the united states: a Markov decision analysis approach. Laryngoscope 2011;121: 952-60 3. Lo WL, Kao SY, Chi LY, et al. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affective survival. J Oral Maxillofac Surg 2003;61:751-58 4. Lee KD, Lu CH, Chen PT, et al. The incidence and risk of developing a second primary esophageal cancer in patients with oral and pharyngeal carcinoma: a population-based study in Taiwan over a 25 year period. BMC Cancer 2009, 9:373 doi:10. 5. Wang WL, Lee CT, Lee YC, et al. Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer. Head Neck 2011; 33: 77–81 6. Muto M, Minashi K, Yano T, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol 2010; 28:1566-1572. 7. Dubuc J, Legoux JL, Winnock M, et al. Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: a prospective study conducted in 62 French endoscopy centers. Endoscopy. 2006;38:690-5 8. Lee YC, Wang CP, Chen CC, et al. Transnasal endoscopy with narrow-band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscope. Gastrointest Endosc. 2009;69:408-417 9. Leon X, Ferlito A, Myer CM, et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol 2002;122:765-778 10. Tincani AJ, Brandalise N, Scaanavini RC, et al. Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer. Head Neck. 2000;22:170-174 11. National comprehensive cancer network clinical guideline for head and neck cancer 2014 12. 口腔癌臨床診療指引2011 財團法人國家衛生研究院 台灣癌症臨床研究合作組織 13. Davidson J, Gilbert R, Irish J, et al. The role of panendoscopy in the management of mucosal head and neck malignancy. A prospective evaluation. Head Neck 2000;22:449-55 14. Shaha AR, Hoover EL, Marti JR, Krespi YP. Is routine triple endoscopy cost-effective in head and neck cancer ? Am J Surg 1988;155:750-3. 15. Su YY, Chen WC, Chuang HC, et al. Effect of routine esophageal screening in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013;139(4):350-354 16. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-oropharyngeal cancer. J Clin Oncol. 2011;29(6);739-746 17. Muto M, Hironaka S, Nakane M, et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc. 2002;56:517-521 18. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6(5):963-8. 19. Wu IC, Lu CY, Kuo FC, et al. Interaction between cigarette, alcool and betel nut use on esophageal cancer risk in Taiwan. Eur J Clin Invest 2006:369:236-241 20. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papilloma virus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011:29:4294 21. Chang F, Syrjanen S, Wang L, et al. Infectious agents in the etiology of esophageal cancer. Gastroenterology 1992; 103:1336 22. Nakagawa K, Koike T, Iijima K, et al. Comparison of the long-term outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan. Am J Gastroneterol. 2014;109(3):348-56 23. Nurkin SJ, Nava HR, Yendomuri S, et al. Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer. Surg Endosc.2014:28:1090-1095 24. Shields TW, LoCicero J, Ponn RB. 2009 General thoracic surgery. 7th ed, 1984-2015.Philadephia;Lippincott Williams & Wilkins 25. Lopes AB, Fagundes RB. Esophageal squamous cell carcinoma: precursor lesions and early diagnosis. World J Gastrointest Endosc. 2012;4(1):9-16. 26. Hashimoto CL, Iriya K, Baba ER, et al. Lugol’s dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am J Gastroenterol. 2005;100(2):275-282. 27. Scheru‥bl H, von Lampe B, Faiss S, et al. Screening for oesophageal neoplasia in patients with head and neck cancer. Br J Cancer. 2002;86(2):239-243. 28. Moschler O, Spahn TW, Middelberg-Bisping C, et al. Chromoendoscopy is a valuable tool for screening of high-risk patients with head and neck cancer for early detection of esophageal cancer. Digestion. 2006;73(2-3):160-166. 29. Uedo N, Fujishiro M, Goda K, et al. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. Dig Endosc. 2011;23(suppl 1):58-71. 30. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. 2011.Applied methods of cost-effectiveness analysis in health care. 1st ed. 179-202. Oxford: Oxford university press 31. Briggs A, Claxton K, Sculpher M. 2006. Decision modeling for health exonomic evaluation. 1st ed. 1-76. Oxford:Oxford university press 32. Beck JR, Pauker SG. The Markov Process in Medical Prognosis. Med Decis Making 1983 4:419-458 33. Sonnenberg FA, Beck JR. Markov models in medical decision making : a practical guide. Med Decis Making 1993; 13: 322-338 34. 全民健康保險醫療費用支付標準102年版 35. Gold MR, Franks P, McCoy KI, et al. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-792 36. de Boer AG, Stalmeier PF, Sprangers MA, et al. Transhiatal vs extended transthoracic resection in esophageal carcinoma: patients’ utilities and treatment preferences. Br J Cancer 2002;86:851-857 37. 中華民國行政院內政部統計處102年簡易生命表 38. Karran A, Blake P, Chan D, et al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. BJS 2014;101:502-510 39. Adenis A, Tresch E, Dewas S, et al. Clinical complete responders to definitive chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013;13:413 40. Shridhar R, Imani-Shikhabadi R, Davis B, et al. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Canc 2013;44:375-84 41. Arduino PG, Carrozzo M, Chiecchio A, et al. Clinical and histopathologic independent prognostic factors in oral squamous cell carcinoma: a retrospective study of 334 cases. J Oral Maxillofac Surg 2008;66:1570-79 42. Teoh AYB, Chiu PWY, Wong TCL, et al. Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg 2011;253:1-5 43. Liao CT, Chang JTC, Wang HM, et al. Salvage therapy in relapsed squamous cell carcinoma of oral cavity: how and when? Cancer 2008;112:94-103 44. Liu SY, Lu CL, Chiou CT, et al. Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan. Oral Oncology 2010;46:276-282 45. Hung SH, Tsai MC, Liu TC, et al. Routine endoscopy for esophageal cancer is suggestive for patients with oral, oropharyngeal and hypopharyngeal cancer.PLOS one 2013;8:e72097 46. Evans J, Fanelli RD, Fisher DA, et al. Adverse events of upper GI endoscopy. Gastrointestinal Endoscope 2012;76:707-718 47. Nurkin SJ, Nava HR, Yendamuri, S, et al. Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer. Surg Endosc 2014;28:1090-1095 48. Isomoto H, Yamaguchi N, Minami H, et al. Management of complications associated with endoscopic submucosal dissection/endoscopic mucosal resection for esophageal cancer. Digestive Endoscopy 2013;25(suppl):29-38 49. Katada C, Muto M, Tanabe S, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection fo esophageal squamous cell carcinoma. Digestive Endoscopy;201325(suppl):39-43 50. Wang CH, Lee YC, Wang CP, et al. Use of transnasal endoscopy for screening of esophageal squamous cee carcinoma in high –risk patients: yield rate, complication, and safety. Digestive endoscopy;2014;26:24-31 51. Dawsey SM, Lewin KJ, Wang GQ, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the sophagus: a prospective follow-up study from Linxian, China. Cancer 1994;74:1686-1692 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56502 | - |
dc.description.abstract | 研究背景:口腔癌發生個案數近年有增加趨勢,在台灣地區2009年男性癌症發生率排名第四,死亡率也是排名第四,病人死亡年齡中位數55歲,比起肺癌造成之死亡年齡中位數提早了十年以上。目前口腔癌病人治療成效良好,第一期病人五年存活率75%,第二期病人五年存活率65.6%,第三期病人五年存活率49%,第四期病人五年存活率30%。雖然口腔癌治療成果改善,但是因為口腔癌病人本身在呼吸道及消化道暴露致癌因子的緣故,罹患第二癌之風險遠高於一般族群,部分病人是死於第二癌而非口腔癌。根據嘉義長庚醫院利用台灣癌登資料庫所做的研究顯示,口腔癌病患罹患之第二癌以食道癌最為顯著增加。然而,在口腔癌病人術後之追蹤項目,上消化道內視鏡篩檢食道癌並非常規例行性檢查,病人通常是在發生吞嚥困難症狀時才接受上消化道內視鏡檢查。在此情況下,食道癌被診斷時通常為較晚期之食道癌,治療結果不佳。
研究目的:本研究探討將上消化道內視鏡檢查列入口腔癌接受根除性治療後之病人術後常規檢查項目,是否能因早期發現食道癌,降低食道癌相關之死亡,改善口腔癌病人之長期存活率。同時探討此政策之耗用資源與效益,是否值得將上消化道內視鏡檢查列入口腔癌病人術後常規檢查。 研究方法:本研究以「馬可夫決策模型」(Markov decision model)進行世代模擬分析(Markov cohort simulation),評估介入策略的經濟效益。介入策略將上消化道內視鏡列為口腔癌病人治療追蹤過程之常規執行項目,探討是否能改善病人之長期存活率及健康狀況,以及該項治療策略所耗用之資源及效益。模擬研究對象為台灣地區口腔癌病人,於初次治療後達到治療後達到「口腔癌緩解」狀態,共1000名男性,其年齡為50歲。每一個週期設定為半年,追蹤10年或至病人死亡為止。對照組為依照目前口腔癌臨床指引每半年接受追蹤檢查。檢查項目並不包括例行性上消化道內視鏡檢查,僅在病人臨床症狀有吞嚥困難時才安排上消化道內視鏡檢查。在口腔癌緩解狀態滿五年後,視為治癒,不再執行例行性追蹤。而實驗組(A)除依照目前臨床指引追蹤外,前五年每半年一次同時接受放大窄頻光源上消化道內視鏡檢查(magnified narrow-band imaging endoscope)至滿五年。實驗組(B)除依照目前臨床指引追蹤外,前五年每一年一次同時接受放大窄頻光源上消化道內視鏡檢查至滿五年。五年之後追蹤方式與對照組相同。當發現口腔癌復發時或發現食道癌時,三組之處理方式相同。經過10年後,比較三組病人存活狀況,包括癌症相關死亡人數、及品質調整生命年數(QALY: quality-adjusted life year)。同時將針對實驗組耗用費用及增加之生存人年,進行成本效益分析,計算每增加一個品質調整生命年數需耗用多少費用(ICER: incremental cost-effectiveness ratio)。參考本國2012年GDP:20336美元,本實驗設定之閾值為新台幣600000/ QALY。 結果:經過10年追蹤後,實驗組(A)存活人數為534人,實驗組(B)存活人數為534人,對照組存活人數為515人。口腔癌相關之死亡,實驗組(A)為327人,實驗組(B)為327人,而對照組為325人。食道癌相關之死亡人數,實驗組(A)為19人,實驗組(B)為20人,而對照組為44人,食道癌相關之死亡人數減少50%以上。在計算品質調整生命年數及耗用費用後,此介入行為實驗組(A)之ICER 值為新台幣198617元/QALY,實驗組(B)實驗組之ICER 值為新台幣148665元/QALY,均低於閾值。 結論:針對口腔癌接受根除性治療後之病人,將上消化道內視鏡檢查列入口腔癌病人術後常規檢查,能因早期發現食道癌降低食道癌之死亡,改善病人之長期存活率。與現行臨床指引相比較,具有經濟效益。 | zh_TW |
dc.description.abstract | Background: The incidence of oral cancer in Taiwan has increased in the past decade. Oral cancer is the 4th leading cause of cancer deaths for males. The median age of death is 55-years of age, at least 10 years younger than those with lung cancer. Treatment and prognosis of oral cancer remain favorable. Patients with stages one through to four have a 5-year survival rate of 75%, 65.5% , 49% and 30% respectively. Although the results of treatment have improved, however, since most of the patients were exposed to the carcinogens such as alcohol, smoking and betel quid, they have a higher incidence of developing secondary cancers. According to the Taiwan Cancer Registry, the most common one being cancer of the esophagus. Between 10- 20 % of patients with oral cancer develop squamous cell carcinoma of the esophagus synchronously or metachronously. Since esophagogastroduodenoscopic (EGD) screening for esophageal cancer is not routinely performed for the follow-up of patients with oral cancer, the diagnosis is usually made only after the symptom of dysphagia occurred. This results in the late diagnosis and consequent poorer prognosis for these patients.
Purpose: The objective of the study is to evaluate the effect and cost-effectiveness of including endoscopic screening of esophageal cancer for patients who received curative treatment for their oral cancer. The authors shall assess whether early detection of esophageal cancer lowers its mortality, and thus improves overall survival rate of oral cancer. Methods: We developed a Markov decision model, in which Markov cohort simulation was used to assess the economic value of this intervention. In this model, 1000 patients with oral cancer aged 50 years of age were enrolled. All patients completed curative treatment and were at the state of remission. In the control group, all patients received postoperative surveillance every 6 months, according to national guidelines, until 60 years of age, or until they die. Esophagogastroduodenoscopy was arranged only when symptoms occur. In the experimental group, 2 different interventional strategies were used. This included screening by EGD (magnified narrow-band imaging endoscope) for esophageal cancer. In group A, EGD was performed every 6 months, and in group B, EGD was performed every year. The primary outcome was the survival difference, difference of quality-adjusted life year (QALY) gained, and incremental cost-effectiveness ratio (ICER). The threshold used to determine the cost-effectiveness was $20336 per QALY. One way sensitivity analysis is done for the important parameters. Results: The number of survivors after 10 years of follow-up was 515 in the control group, and 534 in both experimental groups A (screening every 6 months) and B (screening every year). The number of esophageal cancer related deaths was highest (44) in the control group, 19 in group A, and 20 in group B. respectively. The esophageal cancer related death decreased more than 50% in both EGD screening groups. The mean cost was ($18447, $18885, $18770) respectively. The ICER is $6620 per QALY for the group B, and $4955 per QALY for the group C. Both follow-up strategies were dominant as compared to current strategy. Conclusions: Routine esophagogastroduodenoscopy screening of esophageal cancer in addition to the current postoperative surveillance among patients with oral cancer seem to improve overall survival and is cost-effective. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:31:47Z (GMT). No. of bitstreams: 1 ntu-103-R00848018-1.pdf: 1754247 bytes, checksum: 636b1318238be874f75bcda55fa22f64 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 學位論文審定書 i
謝辭 i 中文摘要 ii 英文摘要 v 第一章 緒論 1 第一節 研究背景 1 第二節 研究目的 3 第二章 文獻探討 4 第一節 台灣地區口腔癌治療現況 4 第二節 口腔癌與食道癌的相關聯性 6 第三節 食道癌之診斷治療 8 第四節 馬可夫決策模型於醫療領域之運用 10 第三章 研究設計與方法 12 第一節 研究架構 12 第二節 研究假說 13 第三節 研究設計 13 一、 研究對象及追蹤時間: 13 二、 治療策略: 15 三、 決策模型中的健康狀態: 19 四、 模型的假設: 24 第四節 統計分析 25 一、 馬可夫決策模型參數 25 二、 運算軟體 29 三、 結果之測量 29 四、 參數不確定性敏感度分析 29 五、 模型的效度 29 第四章 研究結果 30 第一節 模型試算與臨床結果比較 30 第二節 實驗組與對照組存活人數、死因別及食道癌診斷治療狀況 31 第三節 實驗組與對照組的成本效益分析 32 第四節 參數敏感度分析 33 第五章 討論 41 結論 45 參考文獻 46 附錄: 50 表目錄 表格 一 馬可夫模型各項參數 26 表格 二 實驗組與對照組十年後結果 31 表格 三 不同追蹤策略的效用及耗用費用: 32 圖目錄 圖(一) 研究架構 12 圖(二) 食道癌之疾病自然史演變狀態及診斷治療 15 圖(三) 實驗組與對照組被診斷過程之比較 18 圖(四) 健康狀態間之改變 23 圖(五) 不同追蹤策略的效用及耗用費用 33 圖(六) 每年增加一次例行性內視鏡檢查ICER值的敏感度分析 Tornado analysis 34 圖(七) 口腔癌復發率對ICER值的敏感度分析 35 圖(八) 轉移性食道癌對ICER值的敏感度分析 36 圖(九) 食道原位癌轉變為初期食道癌之機率對ICER值的敏感度分析 37 圖(十) 初期食道癌轉變為侵襲性食道癌之機率對ICER值的敏感度分析 38 圖(十一)可接受內視鏡亞黏膜層切除術之機率對ICER值的敏感度分析 39 圖(十二) 每周期食道原位癌發生之機率對ICER值的敏感度分析 40 | |
dc.language.iso | zh-TW | |
dc.title | 台灣地區口腔癌病患術後定期接受上消化道內視鏡篩檢食道癌之成本效益-以馬可夫決策模型進行分析 | zh_TW |
dc.title | The cost-effectiveness of routine esophageal cancer screening by endoscope for oral cancer patients in Taiwan: a Markov decision analysis approach | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林文德,范靜媛 | |
dc.subject.keyword | 口腔癌,食道癌篩檢,經濟效益評估,馬可夫決策模型,上消化道內視鏡檢查, | zh_TW |
dc.subject.keyword | oral cancer,esophageal cancer screening,cost-effectiveness,Markov decision model,esophagogastroduodenoscopy, | en |
dc.relation.page | 55 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-13 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 1.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。